After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.
Digital Camera World

Best photography competitions to enter in March – July 2026: Share your images, get published, and win prizes!

Entering competitions isn't just about winning – though prizes and publicity are great bonuses! It's also a chance to dive ...

After losing $6 billion, Ginkgo Bioworks pivots to selling lab robots with AI

Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ...
Multiple Sclerosis News Today

M&M: Merck, Mayo Clinic team up to use AI to speed drug development in MS

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and other conditions.
Pharmabiz

Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium

Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium: Rahway, New Jersey Saturday, Feb ...

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
STAT

Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Seeking Alpha

Merck: A Buy For 2026, But The Clock Is Still Ticking

Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...

DelveInsight Business Research, LLP: Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption ...
MarketWatch

Merck’s outlook for 2026 comes in below expectations as pipeline faces make-or-break year

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...
Reuters

Merck's 2026 outlook clouds upbeat fourth-quarter results

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...